The comparison of two combination antibiotic [(OAB-T) VS (OAB-F)] regimen trophy in peptic ulcer and dyspepsia patients

Eradication of H. Pylori has an important role in curing peptic ulcer and dyspepsia. Several therapeutic regimens have been offered for eradication of H. Pylori. There are several reports of resistance of H. Pylori to metronidazole in Iran, so other therapeutic regimens have been offered. We compared Furazolidone versus Tetracycline, in quadruple regimen [Omeprazole-Amoxicillin-Bismuth subcitrate-Tetracycline (OAB-T) vs. [Omeprazole-Amoxicillin-Bismuth subcitrate-Furazolidone (OAB-F)]. In a clinical trial study we treated 109 H. Pylori infected patients with dyspepsia in Zahedan Khatam-ol-Anbia Hospital in two therapeutic groups. The first group received Omeprazole 20 mg BID, Bismuth subcitrate 200 mg Q6h, Amoxicillin 1 gr Q12h, Furazolidone 100 mg Q12h. The second group received Omeprazole 20 mg BID, Bismuth subcitrate 200 mg Q6h, Amoxicillin 1 gr Q12h, Tetracycline 500 mg Q 12h. There were 49 patients in OAB-F group and 51 patients in OAB-T group. H. Pylori eradication rate based on H. Pylori fecal Ag Test negativity was 85.7% and 80.4% in OAB-F & OAB-T groups respectively. Furazolidone-based regimen is effective in H. Pylori eradication. With respect to low price and availability of Furazolidone, Furazolidone- based Quadruple therapy is an acceptable regimen in communities with high metronidazole resistance.